Publications 2024

Andersen V, Pingel J, Søfelt HL, Hikmat Z, Johansson M, Pedersen VS, Bertelsen B, Carlsson A, Lindh M, Svavarsdóttir E, Repsilber D, Joergensen MT, Christensen R, Fejrskov A, Füchtbauer JD, Kjeldsen J, Jensen MD, Aalykke C, Rejler M, Høivik ML, Davidsdottir L, Carlson M, Halfvarson J, Zachariassen HH, Petersen LB et al. (2024)
Sex and gender in inflammatory bowel disease outcomes and research
Lancet Gastroenterol Hepatol, 9 (11), 1041-1051
DOI 10.1016/S2468-1253(24)00159-6, PubMed 39395438

Anisdahl K, Lirhus SS, Medhus AW, Moum B, Melberg HO, Høivik ML (2024)
Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study
Dig Liver Dis, 56 (9), 1503-1510
DOI 10.1016/j.dld.2024.02.002, PubMed 38433021

Fejrskov A, Füchtbauer JD, Davíðsdóttir LG, Halfvarson J, Høivik ML, Jensen MD, Mortensen JH, Nielsen LN, Rejler M, Repsilber D, Söderholm JD, Aalykke C, Andersen V, Christensen R, Kjeldsen J (2024)
Novel biomarker profiles to improve individual diagnosis and prognosis in patients with suspected inflammatory bowel disease: protocol for the Nordic inception cohort study (NORDTREAT)
BMJ Open, 14 (5), e083144
DOI 10.1136/bmjopen-2023-083144, PubMed 38754881

Holten KA, Bernklev T, Opheim R, Olsen BC, Detlie TE, Strande V, Ricanek P, Boyar R, Bengtson MB, Aabrekk TB, Asak Ø, Frigstad SO, Kristensen VA, Hagen M, Henriksen M, Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP (2024)
Fatigue in patients with inflammatory bowel disease in remission one year after diagnosis (the IBSEN III study)
J Crohns Colitis (in press)
DOI 10.1093/ecco-jcc/jjae170, PubMed 39527064

Lund C, Strande V, Hagen M, Bengtson MB, Boyar R, Detlie TE, Frigstad SO, Medhus AW, Henriksen M, Holten KIA, Hovde Ø, Huppertz-Hauss G, Johansen I, Olsen BC, Opheim R, Pallenschat J, Perminow G, Ricanek P, Torp R, Ystrøm CM, Høie O, Asak Ø, Vatn S, Aabrekk TB, Kristensen VA et al. (2024)
Low Surgery Rates in Early Crohn's Disease: Results from a Prospective Population-Based Inception Cohort-The Inflammatory Bowel Disease in South-Eastern Norway III Study
Inflamm Bowel Dis (in press)
DOI 10.1093/ibd/izae297, PubMed 39699202

Oliver AJ, Huang N, Bartolome-Casado R, Li R, Koplev S, Nilsen HR, Moy M, Cakir B, Polanski K, Gudiño V, Melón-Ardanaz E, Sumanaweera D, Dimitrov D, Milchsack LM, FitzPatrick MEB, Provine NM, Boccacino JM, Dann E, Predeus AV, To K, Prete M, Chapman JA, Masi AC, Stephenson E, Engelbert J et al. (2024)
Single-cell integration reveals metaplasia in inflammatory gut diseases
Nature, 635 (8039), 699-707
DOI 10.1038/s41586-024-07571-1, PubMed 39567783

Salihovic S, Nyström N, Mathisen CB, Kruse R, Olbjørn C, Andersen S, Noble AJ, Dorn-Rasmussen M, Bazov I, Perminow G, Opheim R, Detlie TE, Huppertz-Hauss G, Hedin CRH, Carlson M, Öhman L, Magnusson MK, Keita ÅV, Söderholm JD, D'Amato M, Orešič M, Wewer V, Satsangi J, Lindqvist CM, Burisch J et al. (2024)
Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease
Nat Commun, 15 (1), 4567
DOI 10.1038/s41467-024-48763-7, PubMed 38830848

Strande V, Høivik ML, Kristensen VA (2024)
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management-Addressing study limitations and the role of psychological resilience-Authors' reply
Aliment Pharmacol Ther, 60 (6), 831-832
DOI 10.1111/apt.18187, PubMed 39072820

Strande V, Lund C, Hagen M, Bengtson MB, Cetinkaya RB, Detlie TE, Frigstad SO, Høie O, Medhus AW, Henriksen M, Aass Holten KI, Hovde Ø, Huppertz-Hauss G, Johansen I, Olsen BC, Opheim R, Ricanek P, Torp R, Tønnessen T, Vatn S, Aabrekk TB, Høivik ML, Kristensen VA (2024)
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort
Aliment Pharmacol Ther, 60 (3), 357-368
DOI 10.1111/apt.18097, PubMed 38837289

Wiken TH, Høivik ML, Anisdahl K, Buer L, Warren DJ, Bolstad N, Hagen M, Moum BA, Medhus AW (2024)
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Crohns Colitis 360, 6 (1), otae013
DOI 10.1093/crocol/otae013, PubMed 38544907

Zerouga I, Valeur J, Sommer C, Cvancarova Småstuen M, Medhus AW, Lund C, Johansen I, Cetinkaya RB, Bengtson MB, Torp R, Hovde Ø, Huppertz-Hauss G, Detlie TE, Aabrekk TB, Ricanek P, Frigstad SO, Hopstock LA, Opheim R, Kristensen VA, Høivik ML, Hauger Carlsen M, Aas AM (2024)
Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
Scand J Gastroenterol, 59 (6), 652-660
DOI 10.1080/00365521.2024.2313056, PubMed 38356408

Publications 2023

Braadland PR, Bergquist A, Kummen M, Bossen L, Engesæter LK, Reims HM, Björk I, Grzyb K, Abildgaard A, Småstuen MC, Folseraas T, Trøseid M, Ulvik A, Ueland PM, Melum E, Line PD, Høivik ML, Grønbæk H, Karlsen TH, Vesterhus M, Hov JR (2023)
Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation
J Hepatol, 79 (4), 955-966
DOI 10.1016/j.jhep.2023.05.038, PubMed 37328069

Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, Kaplan GG, Duricova D, Greenberg D, Melberg HO, Watanabe M, Ahn HS, Targownik L, Pittet VEH, Annese V, Park KT, Katsanos KH, Høivik ML, Krznaric Z, Chaparro M, Loftus EV, Lakatos PL, Gisbert JP, Bemelman W, Moum B et al. (2023)
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
Lancet Gastroenterol Hepatol, 8 (5), 458-492
DOI 10.1016/S2468-1253(23)00003-1, PubMed 36871566

Fossmark R, Lirhus SS, Høivik ML (2023)
The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway
Scand J Gastroenterol, 59 (1), 46-51
DOI 10.1080/00365521.2023.2255710, PubMed 37681998

Holten KIA, Bernklev T, Opheim R, Johansen I, Olsen BC, Lund C, Strande V, Medhus AW, Perminow G, Bengtson MB, Cetinkaya RB, Vatn S, Frigstad SO, Aabrekk TB, Detlie TE, Hovde Ø, Kristensen VA, Småstuen MC, Henriksen M, Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP (2023)
Fatigue in Patients with Newly Diagnosed Inflammatory Bowel Disease: Results from a Prospective Inception Cohort, the IBSEN III Study
J Crohns Colitis, 17 (11), 1781-1790
DOI 10.1093/ecco-jcc/jjad094, PubMed 37279652

Johansen I, Småstuen MC, Løkkeberg ST, Kristensen VA, Høivik ML, Lund C, Olsen B, Strande V, Huppertz-Hauss G, Aabrekk TB, Bengtson MB, Ricanek P, Detlie TE, Frigstad SO, Jelsness-Jørgensen LP, Opheim R (2023)
Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III Study
BMC Gastroenterol, 23 (1), 255
DOI 10.1186/s12876-023-02889-y, PubMed 37501083

Jørgensen KK, Høivik ML, Chopra A, Benth JŠ, Ricanek P, Moum PB, Jyssum I, Bolstad N, Warren DJ, Vaage PJT, Munthe PLA, Lundin PKEA, Anisdahl K, Syversen SW, Goll GL, Lund-Johansen F, Medhus AW, Jahnsen PJ (2023)
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
Scand J Gastroenterol, 58 (8), 874-882
DOI 10.1080/00365521.2023.2177884, PubMed 36788656

Olsen BC, Opheim R, Kristensen VA, Høivik ML, Lund C, Aabrekk TB, Johansen I, Holten K, Strande V, Bengtson MB, Ricanek P, Detlie TE, Bernklev T, Jelsness-Jørgensen LP, Huppertz-Hauss G (2023)
Health-related quality of life in patients with newly diagnosed inflammatory bowel disease: an observational prospective cohort study (IBSEN III)
Qual Life Res, 32 (10), 2951-2964
DOI 10.1007/s11136-023-03435-9, PubMed 37219727

Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K et al. (2023)
Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
NPJ Vaccines, 8 (1), 4
DOI 10.1038/s41541-023-00600-6, PubMed 36697432

Wiken TH, Høivik ML, Buer L, Warren DJ, Bolstad N, Moum BA, Anisdahl K, Småstuen MC, Medhus AW (2023)
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
Scand J Gastroenterol, 58 (8), 863-873
DOI 10.1080/00365521.2023.2176252, PubMed 36799155

Publications 2022

Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K et al. (2022)
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
NPJ Vaccines, 7 (1), 174
DOI 10.1038/s41541-022-00586-7, PubMed 36585405

Zhao M, Lirhus S, Lördal M, Langholz E, Knudsen T, Voutilainen M, Høivik ML, Moum B, Anisdahl K, Saebø B, Haiko P, Malmgren C, Coskun M, Melberg HO, Burisch J (2022)
Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway
Aliment Pharmacol Ther, 56 (6), 989-1006
DOI 10.1111/apt.17145, PubMed 35902223

Publications 2021

Anisdahl K, Svatun Lirhus S, Medhus AW, Moum B, Melberg HO, Høivik ML (2021)
First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study
Scand J Gastroenterol, 56 (10), 1163-1168
DOI 10.1080/00365521.2021.1955147, PubMed 34320885

Kristensen VA, Opheim R, Perminow G, Huppertz-Hauss G, Detlie TE, Lund C, Andersen S, Olsen BC, Johansen I, Medhus AW, Vatn S, Brackmann S, Olbjørn C, Rove J, Henriksen M, Løvlund EE, Bengtson MB, Aabrekk TB, Tønnessen T, Vikskjold FB, Yassin H, Frigstad SO, Hasund A, Høie O, Schmidt K et al. (2021)
Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway
Scand J Gastroenterol, 56 (8), 899-905
DOI 10.1080/00365521.2021.1922746, PubMed 34154494

Lirhus SS, Høivik ML, Moum B, Anisdahl K, Melberg HO (2021)
Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study
Clin Epidemiol, 13, 287-294
DOI 10.2147/CLEP.S303797, PubMed 33935519

Sousa P, Ministro P, Armuzzi A, Dignass A, Høivik ML, Barreiro-de Acosta M, Vavricka S, Saad-Hossne R, Kotze PG, Peyrin-Biroulet L, Magro F (2021)
Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease
Dig Liver Dis, 53 (12), 1571-1579
DOI 10.1016/j.dld.2021.05.038, PubMed 34187768

Publications 2020

Klepp P, Brackmann S, Cvancarova M, Hoivik ML, Hovde Ø, Henriksen M, Huppertz-Hauss G, Bernklev T, Hoie O, Kempski-Monstad I, Solberg IC, Stray N, Jahnsen J, Vatn MH, Moum B (2020)
Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study
BMJ Open Gastroenterol, 7 (1), e000361
DOI 10.1136/bmjgast-2019-000361, PubMed 32337058

Kravdal Ø, Magnus P, Moum B, Høivik ML (2020)
Association of Childbearing With a Short-Term Reduced Risk of Crohn Disease in Mothers
Am J Epidemiol, 189 (4), 294-304
DOI 10.1093/aje/kwz285, PubMed 31907543

Kristensen VA, Cvancarova M, Høivik ML, Moum B, Vatn MH (2020)
Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study
Scand J Gastroenterol, 55 (4), 436-441
DOI 10.1080/00365521.2020.1745879, PubMed 32252542

Kummen M, Thingholm LB, Rühlemann MC, Holm K, Hansen SH, Moitinho-Silva L, Liwinski T, Zenouzi R, Storm-Larsen C, Midttun Ø, McCann A, Ueland PM, Høivik ML, Vesterhus M, Trøseid M, Laudes M, Lieb W, Karlsen TH, Bang C, Schramm C, Franke A, Hov JR (2020)
Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis
Gastroenterology, 160 (5), 1784-1798.e0
DOI 10.1053/j.gastro.2020.12.058, PubMed 33387530

Ossum AM, Palm Ø, Cvancarova M, Bernklev T, Jahnsen J, Moum B, Høivik ML, IBSEN Study Group (2020)
The Impact of Spondyloarthritis and Joint Symptoms on Health-Related Quality of Life and Fatigue in IBD Patients. Results From a Population-Based Inception Cohort (20-Year Follow-up in the Ibsen Study)
Inflamm Bowel Dis, 26 (1), 114-124
DOI 10.1093/ibd/izz105, PubMed 31127829

Publications 2019

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML (2019)
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Scand J Gastroenterol, 54 (1), 41-48
DOI 10.1080/00365521.2018.1548646, PubMed 30650312

Frigstad SO, Høivik ML, Jahnsen J, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Bernklev T, Moum B, Jelsness-Jørgensen LP (2019)
Pain Severity and Vitamin D Deficiency in IBD Patients
Nutrients, 12 (1)
DOI 10.3390/nu12010026, PubMed 31877637

Publications 2018

Buer LCT, Høivik ML, Warren DJ, Medhus AW, Moum BA (2018)
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Inflamm Bowel Dis, 24 (5), 997-1004
DOI 10.1093/ibd/izx110, PubMed 29668901

Frigstad SO, Høivik ML, Jahnsen J, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Bernklev T, Moum B, Jelsness-Jørgensen LP (2018)
Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients
World J Gastroenterol, 24 (29), 3293-3301
DOI 10.3748/wjg.v24.i29.3293, PubMed 30090009

Henriksen M, Høivik ML, Jelsness-Jørgensen LP, Moum B, IBSEN Study Group (2018)
Irritable Bowel-like Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results From a Population-based Study [the IBSEN Study]
J Crohns Colitis, 12 (4), 389-393
DOI 10.1093/ecco-jcc/jjx152, PubMed 29186372

Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW (2018)
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Scand J Gastroenterol, 53 (6), 692-699
DOI 10.1080/00365521.2018.1463391, PubMed 29852793

Lirhus SS, Høivik ML, Moum B, Melberg HO (2018)
Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study
Scand J Gastroenterol, 53 (8), 952-957
DOI 10.1080/00365521.2018.1495258, PubMed 30205699

Ossum AM, Palm Ø, Cvancarova M, Solberg IC, Vatn M, Moum B, Høivik ML, IBSEN study group (2018)
Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study
Scand J Gastroenterol, 53 (10-11), 1250-1256
DOI 10.1080/00365521.2018.1518482, PubMed 30353756

Ossum AM, Palm Ø, Lunder AK, Cvancarova M, Banitalebi H, Negård A, Høie O, Henriksen M, Moum BA, Høivik ML, IBSEN Study Group (2018)
Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study
J Crohns Colitis, 12 (1), 96-104
DOI 10.1093/ecco-jcc/jjx126, PubMed 28961700

Publications 2017

Buer L, Høivik ML, Medhus AW, Moum B (2017)
Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
Dig Dis, 35 (1-2), 74-82
DOI 10.1159/000449087, PubMed 28147370

Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML (2017)
Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study
J Crohns Colitis, 11 (3), 297-304
DOI 10.1093/ecco-jcc/jjw166, PubMed 27660339

Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA (2017)
Corrigendum: Malignancies in Patients with Inflammatory Bowel Disease (IBD): Results from 20 Years of Follow-up in the IBSEN (Inflammatory Bowel South-Eastern Norway) Study
J Crohns Colitis, 11 (12), 1511
DOI 10.1093/ecco-jcc/jjw218, PubMed 28039308

Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA (2017)
Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study
J Crohns Colitis, 11 (5), 571-577
DOI 10.1093/ecco-jcc/jjw193, PubMed 28453756

Tronstad RR, Kummen M, Holm K, von Volkmann HL, Anmarkrud JA, Høivik ML, Moum B, Gilja OH, Hausken T, Baines J, Karlsen TH, Fiskerstrand T, Hov JR (2017)
Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease
Inflamm Bowel Dis, 23 (10), 1752-1761
DOI 10.1097/MIB.0000000000001264, PubMed 28902124

Publications 2016

Hovde Ø, Småstuen MC, Høivik ML, Bernklev T, Huppertz-Hauss G, Høie O, Jahnsen J, Stray N, Henriksen M, Solberg IC, Moum BA (2016)
Mortality and Causes of Death in Ulcerative Colitis: Results from 20 Years of Follow-up in the IBSEN Study
Inflamm Bowel Dis, 22 (1), 141-5
DOI 10.1097/MIB.0000000000000582, PubMed 26355464

Huppertz-Hauss G, Høivik ML, Jelsness-Jørgensen LP, Opheim R, Henriksen M, Høie O, Hovde Ø, Kempski-Monstad I, Solberg IC, Jahnsen J, Hoff G, Moum B, Bernklev T (2016)
Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study
Scand J Gastroenterol, 52 (3), 351-358
DOI 10.1080/00365521.2016.1256425, PubMed 27852169

Jørgensen SF, Trøseid M, Kummen M, Anmarkrud JA, Michelsen AE, Osnes LT, Holm K, Høivik ML, Rashidi A, Dahl CP, Vesterhus M, Halvorsen B, Mollnes TE, Berge RK, Moum B, Lundin KE, Fevang B, Ueland T, Karlsen TH, Aukrust P, Hov JR (2016)
Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation
Mucosal Immunol, 9 (6), 1455-1465
DOI 10.1038/mi.2016.18, PubMed 26982597

Kummen M, Holm K, Anmarkrud JA, Nygård S, Vesterhus M, Høivik ML, Trøseid M, Marschall HU, Schrumpf E, Moum B, Røsjø H, Aukrust P, Karlsen TH, Hov JR (2016)
The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls
Gut, 66 (4), 611-619
DOI 10.1136/gutjnl-2015-310500, PubMed 26887816

Lunder AK, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, Viktil E, Henriksen M, Hovde Ø, Huppertz-Hauss G, Høie O, Høivik ML, Monstad I, Solberg IC, Jahnsen J, Karlsen TH, Moum B, Vatn M, Negård A (2016)
Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease
Gastroenterology, 151 (4), 660-669.e4
DOI 10.1053/j.gastro.2016.06.021, PubMed 27342213

Wanderås MH, Moum BA, Høivik ML, Hovde Ø (2016)
Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies
World J Gastrointest Pharmacol Ther, 7 (2), 235-41
DOI 10.4292/wjgpt.v7.i2.235, PubMed 27158539

Publications 2015

Huppertz-Hauss G, Høivik ML, Langholz E, Odes S, Småstuen M, Stockbrugger R, Hoff G, Moum B, Bernklev T (2015)
Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis
Inflamm Bowel Dis, 21 (2), 337-44
DOI 10.1097/MIB.0000000000000272, PubMed 25569735

Solberg IC, Høivik ML, Cvancarova M, Moum B, IBSEN Study Group (2015)
Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)
Scand J Gastroenterol, 50 (12), 1456-62
DOI 10.3109/00365521.2015.1064991, PubMed 26139389

Publications 2014

Moum B, Hovde Ø, Høivik ML (2014)
What have we learnt about the role of the environment and natural course of IBD in the new millennium? 20-year follow-up of the IBSEN cohort
Dig Dis, 32 Suppl 1, 2-9
DOI 10.1159/000367818, PubMed 25531347

Publications 2013

Høivik ML, Reinisch W, Cvancarova M, Moum B, IBSEN study group (2013)
Anaemia in inflammatory bowel disease: a population-based 10-year follow-up
Aliment Pharmacol Ther, 39 (1), 69-76
DOI 10.1111/apt.12541, PubMed 24172277

Publications 2012

Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T, IBSEN Group (2012)
Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study
Gut, 62 (3), 368-75
DOI 10.1136/gutjnl-2012-302311, PubMed 22717453

Publications 2011

Hoivik ML, Moum B, Solberg IC, Cvancarova M, Hoie O, Vatn MH, Bernklev T, IBSEN Study Group (2011)
Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study
Inflamm Bowel Dis, 18 (8), 1540-9
DOI 10.1002/ibd.21863, PubMed 21936030

Høivik ML, Bernklev T, Solberg IC, Cvancarova M, Lygren I, Jahnsen J, Moum B, IBSEN Study Group (2011)
Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study
J Crohns Colitis, 6 (4), 441-53
DOI 10.1016/j.crohns.2011.10.001, PubMed 22398064

Opheim R, Hoivik ML, Solberg IC, Moum B, IBSEN Study Group (2011)
Complementary and alternative medicine in patients with inflammatory bowel disease: the results of a population-based inception cohort study (IBSEN)
J Crohns Colitis, 6 (3), 345-53
DOI 10.1016/j.crohns.2011.09.007, PubMed 22405172

Publications 2010

Hoivik ML, Bernklev T, Moum B (2010)
Need for standardization in population-based quality of life studies: a review of the current literature
Inflamm Bowel Dis, 16 (3), 525-36
DOI 10.1002/ibd.21032, PubMed 19637337